ATAGI and the Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) have released a joint statement surrounding the administration of COVID-19 AstraZeneca and 血栓形成伴血小板减少症候群 (TTS).
Following close monitoring of local and international data it has been noted that the risk of TTS is not likely to be increased in people who:
- Have a history of blood clots in typical sites
- Have an increased clotting tendency that is not immune mediated
- Have a family history of blood clots
- Have a history of ischaemic heart disease
- Currently have or has a history of thrombocytopenia
- Are receiving anticoagulation therapy
Comirnaty™ is the preferred COVID-19 vaccine for people who:
- Have a history of idiopathic splanchnic vein thrombosis
- Have a history of antiphospholipid syndrome with thrombosis
- Individuals < 50 years of age
- Have a history of cerebral venous sinus thrombosis (CVST)
- Have a history of heparin-induced thrombocytopenia (HIT)
- Have a contraindication to COVID-19 AstraZeneca (including anaphylaxis to a previous dose or anaphylaxis to a component of COVID-19 AstraZeneca, TTS occurring after a dose of COVID-19 AstraZeneca or other serious adverse event following receipt of COVID-19 AstraZeneca)
要阅读该声明全文,请参阅以下链接: